Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 84.52% is 10% below its 5-year average of 93.99%, near the high end of its 5-year range (4.67%–100.00%).
2.10% below its 12-month average of 86.33%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 96.16%.
GROSS MARGIN
84.52%
GROSS MARGIN AVG TTM
86.33%
GROSS MARGIN AVG 3Y
72.44%
GROSS MARGIN AVG 5Y
93.99%
GROSS MARGIN AVG 10Y
53.97%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2.10%
CURRENT VS 3Y AVG
+16.68%
CURRENT VS 5Y AVG
-10.07%
CURRENT VS 10Y AVG
+56.62%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+104.25%
vs the sector median at left
Zevra Therapeutics, Inc.
Market Cap
$632.95M
Gross Margin
84.52%
TTM Avg
86.33%
3Y Avg
72.44%
5Y Avg
93.99%
Market Cap
$632.51M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$637.85M
Gross Margin
-58.05%
TTM Avg
20.98%
3Y Avg
10.49%
5Y Avg
14.13%
Market Cap
$620.13M
Gross Margin
66.63%
TTM Avg
64.65%
3Y Avg
65.95%
5Y Avg
64.74%
Market Cap
$658.16M
Gross Margin
91.05%
TTM Avg
-190849.07%
3Y Avg
-96132.87%
5Y Avg
-64176.88%
Market Cap
$658.58M
Gross Margin
15.69%
TTM Avg
15.20%
3Y Avg
15.20%
5Y Avg
15.20%
Market Cap
$660.66M
Gross Margin
100.27%
TTM Avg
50.13%
3Y Avg
25.07%
5Y Avg
10.71%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | $632.95M | 84.52% | 86.33% | 72.44% | 93.99% |
| Aura Biosciences, Inc. (AURA)vs › | $632.51M | 0.00% | 0.00% | 0.00% | 0.00% |
| Prime Medicine, Inc. (PRME)vs › | $637.85M | -58.05% | 20.98% | 10.49% | 14.13% |
| OmniAb, Inc. (OABI)vs › | $621.21M | -18.17% | 40.91% | 70.46% | 80.30% |
| SOPHiA GENETICS S.A. (SOPH)vs › | $620.13M | 66.63% | 64.65% | 65.95% | 64.74% |
| Climb Bio, Inc. (CLYM)vs › | $611.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $658.16M | 91.05% | -190849.07% | -96132.87% | -64176.88% |
| Starling Oncology, Inc. (STLN)vs › | $658.58M | 15.69% | 15.20% | 15.20% | 15.20% |
| Helus Pharma Inc. (HELP)vs › | $660.66M | 100.27% | 50.13% | 25.07% | 10.71% |
| Annexon, Inc. (ANNX)vs › | $664.38M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
84.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 96.16% |
| 2026-03-31 | 93.75% |
| 2025-12-31 | 95.55% |
| 2025-09-30 | 94.04% |
| 2025-06-30 | 52.17% |
| 2025-03-31 | 93.41% |
| 2024-12-31 | 88.66% |
| 2024-09-30 | 37.67% |
| 2024-06-30 | 19.69% |
| 2024-03-31 | 4.67% |
| 2023-12-31 | 78.92% |
| 2023-09-30 | 95.03% |
| 2023-06-30 | 92.01% |
| 2023-03-31 | 96.06% |
| 2022-12-31 | 93.83% |
| 2022-09-30 | 95.09% |
| 2022-06-30 | 96.08% |
| 2022-03-31 | 99.80% |
| 2021-12-31 | 97.71% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 91.66% |
| 2021-03-31 | 91.75% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 90.71% |
| 2020-03-31 | 68.26% |
| 2019-12-31 | -41.35% |
| 2019-09-30 | 91.28% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
